By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen-Cilag AG 

Sihlbruggstrasse 111

Baar    6340  Switzerland
Phone: 41-41-7673434 Fax: 41-41-7673400





Company News
Janssen-Cilag AG Release: Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit With Single Agent Imbruvica (Ibrutinib) Vs Temsirolimus At First Relapse In Mantle Cell Lymphoma 6/19/2017 4:49:49 AM
Janssen-Cilag AG Release: DARZALEX (Daratumumab) Receives Positive CHMP Opinion For The Treatment Of Multiple Myeloma In Patients Who Have Received At Least One Prior Therapy 2/24/2017 6:58:43 AM
Janssen-Cilag AG Submits Marketing Authorisation Application For Darunavir-Based Single Tablet Regimen For Treatment Of HIV-1 To EMA 9/12/2016 11:33:03 AM
National Institute for Clinical Excellence (NICE) Rejects Early Use Of Janssen-Cilag AG's Velcade For Multiple Myeloma 11/12/2013 7:35:59 AM
Janssen-Cilag AG Release: ZYTIGA® Approved in the EU for Use in the Treatment of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy 1/11/2013 10:00:52 AM
Janssen-Cilag AG Acquires CorImmun 6/28/2012 10:31:03 AM
Basilea Pharmaceutica (BSLN.SW) Announces Discontinuation of Sale of Ceftobiprole by Janssen-Cilag AG, a Johnson & Johnson (JNJ) Company, In Switzerland 9/9/2010 7:03:45 AM
Janssen-Cilag AG Submits Marketing Authorisation Application in Europe for Paliperidone Palmitate for the Treatment of Schizophrenia 12/4/2009 10:14:44 AM
Janssen-Cilag AG Announces CHMP Delays European Commission Decision Process to Approve ZEVTERATM 2/24/2009 7:58:43 AM
PPD, Inc. (PPDI) to Receive Milestone Payments for First Regulatory Approvals of Priligy(TM) (Dapoxetine) in Finland and Sweden for Treatment of Premature Ejaculation 2/10/2009 10:07:18 AM